Drugs & Targets FDA approves Enhertu as first HER2-directed therapy for breast cancer January 31, 2025Vol.51 No.04
Drugs & Targets FDA approves Grafapex as preparative regiment for allogeneic hematopoietic stem cell transplantation in AML or MDS January 31, 2025Vol.51 No.04
Drugs & Targets Yunu, WCG collaborate to support clinical trial imaging services January 31, 2025Vol.51 No.04
Drugs & Targets FDA grants RP1 BLA priority review for advanced melanoma January 24, 2025Vol.51 No.03
Drugs & Targets FDA approves sotorasib + panitumumab for KRAS G12C-mutated colorectal cancer January 17, 2025Vol.51 No.02
Drugs & Targets FDA approves acalabrutinib + bendamustine and rituximab for mantle cell lymphoma January 17, 2025Vol.51 No.02
Drugs & Targets FDA issues proposed rule to limit nicotine in cigarettes January 17, 2025Vol.51 No.02
Drugs & Targets FDA revokes authorization of Red No. 3 in food and ingested drugs January 17, 2025Vol.51 No.02
Drugs & Targets FDA grants Rare Pediatric Disease designation for THIO in pediatric high-grade gliomas January 17, 2025Vol.51 No.02
